P

$PODD

3 articles found
1 positive
1 negative
1 neutral
The Motley FoolThe Motley Fool··Jonathan Ponciano

EyePoint Pharmaceuticals Attracts $20M Strategic Investment Amid 93% Annual Surge

Parkman Healthcare Partners invests $20M in EyePoint Pharmaceuticals as shares surge 93% annually ahead of mid-2026 Phase 3 data for retinal disease treatment DURAVYU.
CVSDXCMEYPTPODDbiotechPhase 3 trials
BenzingaBenzinga··Vandana Singh

Insulet Plunges to 52-Week Low After Omnipod 5 Safety Recall

Insulet stock hits 52-week low after voluntary Omnipod 5 recall due to insulin delivery tubing defect. 18 serious adverse events reported.
XHEPODDBCSMTMATtechnical analysis52-week low
BenzingaBenzinga··Prnewswire

Digital Health Expansion Accelerates as Market Reaches $6 Trillion Milestone

Global health market reaches $6 trillion milestone by 2026, driven by consumer demand for wellness products. Companies expand through innovation in digital health, pharmaceuticals, and specialized care solutions.
VKTXAMRXPBHPODDobesity treatmenthealth and wellness market